Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis, a generic pharmaceutical company, has acquired the brand name drug Kadian from King Pharmaceuticals, a vertically integrated pharmaceutical company, for not more than $127.5m, based on quarterly sales related milestones, ending June 30, 2010.
Subscribe to our email newsletter
Kadian which is an extended release morphine sulfate product is the first originator brand product to be marketed by Actavis US. The company anticipates marketing Kadian only in the US.
Kadian, used to treat moderate to severe chronic pain, is currently marketed in 20mg, 30mg, 50mg, 60mg, 80mg, 100mg and 200mg dosage strength capsules. Kadian’s wide range of dosage strengths allows physicians to give patients more treatment options in managing their pain, the company said.
Doug Boothe, CEO of Actavis US, said: The acquisition of Kadian is the latest step in Actavis’s strategy to expand our specialty drug portfolio and is well aligned with our emphasis on bringing complex controlled-release products to the marketplace. Kadian has enjoyed significant market share and we are excited about its continued prospects as a drug that benefits many patients.
Earlier in December, Actavis has reached an agreement on a Consent Decree of Permanent Injunction with the Food and Drug Administration (FDA) regarding the company’s Actavis Totowa LLC subsidiary.